LGALS1 and breast cancer: Thiodigalactoside, a carbohydrate-based galectin-1 inhibitor, has been shown to prevent angiogenesis and tumor growth while preventing metastasis and inducing the apoptosis of tumor cells in breast cancer samples in tumor mouse models [15].